Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 4Solid Tumors 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Diseases 1Colorectal Neoplasms 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × RG7388 × Clear all
NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Hoffmann-La Roche

Phase 1/2 Terminated
38 enrolled 34 charts
CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03850535 2022-06-21

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Hoffmann-La Roche

Phase 1/2 Terminated
24 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02545283 2022-01-11

MIRROS

Hoffmann-La Roche

Phase 3 Terminated
447 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02670044 2022-01-03

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Hoffmann-La Roche

Phase 1 Completed
88 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡